Leerink Partnrs Issues Pessimistic Outlook for INSP Earnings

Inspire Medical Systems, Inc. (NYSE:INSP) – Leerink Partnrs dropped their FY2028 EPS estimates for shares of Inspire Medical Systems in a report released on Tuesday, February 11th. Leerink Partnrs analyst M. Kratky now forecasts that the company will earn $5.62 per share for the year, down from their previous forecast of $5.69. The consensus estimate for Inspire Medical Systems’ current full-year earnings is $1.33 per share.

A number of other equities research analysts also recently issued reports on INSP. Stifel Nicolaus decreased their price target on shares of Inspire Medical Systems from $200.00 to $190.00 and set a “hold” rating on the stock in a research note on Tuesday, January 21st. Royal Bank of Canada restated an “outperform” rating and set a $260.00 target price on shares of Inspire Medical Systems in a research report on Tuesday. KeyCorp reiterated an “overweight” rating and issued a $234.00 price target (down previously from $236.00) on shares of Inspire Medical Systems in a research report on Friday, January 24th. Wells Fargo & Company decreased their price objective on Inspire Medical Systems from $198.00 to $195.00 and set an “equal weight” rating on the stock in a research report on Tuesday. Finally, Piper Sandler lowered their price objective on Inspire Medical Systems from $260.00 to $233.00 and set an “overweight” rating for the company in a research note on Monday. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $228.82.

Inspire Medical Systems Stock Performance

NYSE INSP opened at $183.17 on Wednesday. The stock has a 50 day moving average price of $189.39 and a 200-day moving average price of $191.39. Inspire Medical Systems has a one year low of $123.00 and a one year high of $257.40. The company has a market capitalization of $5.49 billion, a P/E ratio of 171.18 and a beta of 1.32.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings results on Monday, February 10th. The company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a return on equity of 5.30% and a net margin of 4.37%.

Hedge Funds Weigh In On Inspire Medical Systems

A number of hedge funds have recently added to or reduced their stakes in INSP. First Horizon Advisors Inc. boosted its holdings in shares of Inspire Medical Systems by 885.7% in the fourth quarter. First Horizon Advisors Inc. now owns 138 shares of the company’s stock valued at $26,000 after purchasing an additional 124 shares during the period. True Wealth Design LLC purchased a new stake in shares of Inspire Medical Systems in the 3rd quarter worth $30,000. Farther Finance Advisors LLC grew its position in shares of Inspire Medical Systems by 1,158.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 151 shares of the company’s stock worth $32,000 after buying an additional 139 shares in the last quarter. Harbour Investments Inc. increased its stake in shares of Inspire Medical Systems by 101.0% during the fourth quarter. Harbour Investments Inc. now owns 197 shares of the company’s stock valued at $37,000 after buying an additional 99 shares during the period. Finally, GAMMA Investing LLC raised its holdings in shares of Inspire Medical Systems by 559.3% in the third quarter. GAMMA Investing LLC now owns 178 shares of the company’s stock valued at $38,000 after acquiring an additional 151 shares in the last quarter. 94.91% of the stock is currently owned by institutional investors.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.